In this webinar, you’ll hear from Paul Vauterin. He is currently CIO of Aelin Therapeutics, a biotech company leveraging targeted protein aggregation to develop an entirely new class of therapeutics aiming at hard-to-treat targets in cancer and infectious diseases. Paul is responsible for bioinformatics and data science activities, which are crucial elements of the company’s drug discovery and development platform.
And also, James Longden, Head of Discovery Biology at E-therapeutics, a biotech company that integrates computational power and biology to discover life-transforming RNAi medicines. James is focused on big data biology and machine learning to predict systems-wide changes driving the disease.
What you will learn
Data delivers value in drug discovery
How data science and computational strategy can deliver value in drug discovery and development and pioneering an end-user approach E-therapeutics and Aelin will share how they are unlocking value.
Harmonizing siloed data
How ONTOFORCE’s DISQOVER knowledge management solution brings insights fast to accelerate R&D decision making. Harmonizing siloed, disparate data in a flexible, easy-to-use user interface brings results quickly and at scale.
Increasing data literacy
How barriers to data science adoption can be addressed and best practices for demonstrating the value to the end user. Approaches to change management and measuring the impact of solutions.
Enabling data for AI and machine learning
How harmonized data can unlock opportunities in AI and machine learning for drug discovery & development. A deep dive into the e-therapeutics approach of enabling data for AI, machine learning, and graph neural networks.
Knowledge graph for non-technical users
Knowledge graphs accelerate drug discovery – by harmonizing disparate, siloed data across biopharma companies. How DISQOVER helps to visualize the knowledge graph for non-technical users.